Substance use and abuse among pregnant women is a major public health issue. Headache during pregnancy is a frequent event due to hormonal imbalance.1 Combination products containing butalbital with caffeine and an analgesic, acetaminophen, aspirin or codeine are prescribed for the treatment of migraine and tension-type headaches.2 We report here a case of barbiturate neonatal abstinence syndrome (NAS) and caffeine-related Intra-Uterine Growth Restriction (IUGR) due to maternal abuse of a combination drug made from butalbital, caffeine and propyphenazone (Optalidon®), diagnosed after suggestive clinical features
Neonatal abstinence syndrome and intra-uterine growth restriction secondary to maternal antimigraine drug abuse / Marco, Cirronis; Giulia M., Vezzoni; Nicoletta G., Depaulis; Maria E., Capra; Biasucci, G; Carlo A., Locatelli. - In: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. - ISSN 1742-7835. - 128:(2021), pp. 625-627. [10.1111/bcpt.13514]
Neonatal abstinence syndrome and intra-uterine growth restriction secondary to maternal antimigraine drug abuse
Biasucci G;
2021-01-01
Abstract
Substance use and abuse among pregnant women is a major public health issue. Headache during pregnancy is a frequent event due to hormonal imbalance.1 Combination products containing butalbital with caffeine and an analgesic, acetaminophen, aspirin or codeine are prescribed for the treatment of migraine and tension-type headaches.2 We report here a case of barbiturate neonatal abstinence syndrome (NAS) and caffeine-related Intra-Uterine Growth Restriction (IUGR) due to maternal abuse of a combination drug made from butalbital, caffeine and propyphenazone (Optalidon®), diagnosed after suggestive clinical featuresI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
